In an older adult with rheumatoid arthritis, which IL‑6 inhibitor is safer: Actemra (tocilizumab) or Kevzara (sarilumab)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Actemra (tocilizumab) and Kevzara (sarilumab) have comparable safety profiles in older adults with rheumatoid arthritis, with no clinically meaningful differences in adverse events between the two IL-6 inhibitors.

Direct Comparative Safety Evidence

The most direct head-to-head comparison shows equivalent safety between these agents. The ASCERTAIN trial directly compared sarilumab and tocilizumab and found no clinically meaningful differences in treatment-emergent adverse events 1. Both drugs demonstrated similar patterns of laboratory changes including decreased neutrophils and platelets, and increased transaminases and lipids 1. Importantly, there was no association between decreased absolute neutrophil counts and increased infection incidence with either agent 1.

Age-Specific Safety Considerations

For older adults specifically, both agents require similar caution:

  • Kevzara (sarilumab): The FDA label notes that among patients ≥65 years, the frequency of serious infections was higher compared to younger patients, though no overall safety differences were observed between age groups 2. The label specifically states "caution should be used when treating the elderly" 2.

  • Actemra (tocilizumab): Recent Japanese postmarketing surveillance data from 2025 suggests tocilizumab is generally well tolerated in older patients with RA and does not increase cardiovascular events or malignancies 3. However, one 2024 study found tocilizumab had an increased risk of serious infections compared to TNF inhibitors (aHR 2.493 [1.275-4.876]) 4, and in patients ≥75 years, etanercept showed better safety than tocilizumab (aRR 2.40 [1.24-4.61] for tocilizumab) 4.

Key Safety Patterns Common to Both

Both IL-6 inhibitors share these safety considerations:

  • Infection risk: Elevated compared to general population (aHR 3.65 [3.13-4.25] for herpes zoster with b/tsDMARDs) 4
  • Laboratory monitoring: Both require monitoring for neutropenia, thrombocytopenia, elevated transaminases, and lipid changes 1
  • Elderly population: Higher baseline infection risk necessitates heightened vigilance with either agent 2

Clinical Decision Algorithm

Choose either agent based on:

  1. Route preference: Tocilizumab offers both IV and subcutaneous formulations 5; sarilumab is subcutaneous only 2
  2. Dosing convenience: Tocilizumab IV every 4 weeks vs sarilumab subcutaneous every 2 weeks
  3. Prior exposure: If one agent failed due to intolerance, cycling to the other IL-6 inhibitor is reasonable 6
  4. Comorbidities: Both have similar cardiovascular and malignancy profiles in older adults 3

Important Caveats

  • Network meta-analysis evidence shows both agents provide clinically important ACR50 responses: sarilumab (OR 3.11 [1.25-7.76]) and tocilizumab 8 mg/kg IV (OR 10.03 [3.65-31.27]) compared to placebo 7
  • The slightly higher odds ratio for tocilizumab 8 mg/kg should be interpreted cautiously as this reflects efficacy, not safety superiority
  • Most critical point: The 2026 EULAR safety review found one study showing increased serious infection risk with tocilizumab versus TNF inhibitors specifically 4, but this was not consistently replicated across all studies

Bottom line for older adults: Neither agent demonstrates clear safety superiority. Select based on practical factors (route, dosing frequency) and monitor both agents identically for infections, laboratory abnormalities, and age-related complications.

Related Questions

Is Actemra (tocilizumab) safe for a rheumatoid arthritis patient with diabetes and fatty liver disease who has failed adalimumab therapy?
Is Tyenne (tocilizumab‑aazg) as effective as tocilizumab for adult patients with moderate to severe rheumatoid arthritis refractory to disease‑modifying antirheumatic drugs?
When should tocilizumab be administered relative to antibiotics, and is prophylactic antibiotic use indicated, or what empiric antibiotic therapy is recommended if a bacterial infection is suspected?
In a rheumatoid‑arthritis patient who cannot receive rituximab because an infusion center is unavailable and who had cancer within the past year, can sarilumab (Kevzara) be used safely as an alternative IL‑6‑receptor antagonist?
In a 64‑year‑old man with rheumatoid arthritis treated with tocilizumab, what differential diagnosis is suggested by long‑standing low serum globulins, thrombocytopenia (~100 × 10⁹/L), mild leukopenia (~4 × 10⁹/L), normal hemoglobin and hematocrit, and a slowly increasing macrocytosis (MCV ~101 fL) with rising MCH and stable MCHC?
What is the procedural code for removal of internal fixation hardware from a left clavicle after ORIF?
What is the recommended megestrol acetate dosing for appetite stimulation in a patient with an eGFR of 59 ml/min/1.73 m²?
Do bed‑bug bites cause itching and burning, and how should they be treated?
What is the likely cause and recommended evaluation for a 5‑year‑old boy with brief, sporadic episodes of micropsia (seeing people with unusually small heads) occurring 2–3 times daily and resolving spontaneously?
What is the appropriate management for a patient with a suppressed TSH of 0.29 mIU/L and an elevated T4 of 13.9 µg/dL?
In a patient with a thyroid panel showing TSH 0.29 µIU/L, free T4 13.9 pmol/L, and free T3 4.5 pmol/L, what is the likely diagnosis and appropriate management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.